Aim: This study aimed to evaluate the efficacy, safety, and tolerability of brexpiprazole compared to placebo in Japanese patients with acute schizophrenia (SCZ).
receptors, all with subnanomolar potency. 5 It has a lower intrinsic activity at the dopamine D 2 receptor and stronger antagonism at the serotonin 5-HT 2A receptor than aripiprazole, the first dopamine D 2 partial agonist approved for the treatment of SCZ. 5 Results obtained from two global, 6-week, phase 3 studies of brexpiprazole demonstrated that it was effective, safe, and well tolerated in the treatment of acute SCZ. 6, 7 In these trials, the average effects of the 2-and 4-mg brexpiprazole doses on the Positive and Negative Syndrome Scale (PANSS) total score were statistically significant compared with placebo at week 6. In a meta-analysis of the two trials, both the 2-and 4-mg groups showed efficacy versus the placebo group. 8 According to the pooled data analysis from one phase 2 and two short-term studies, brexpiprazole was well tolerated and had a favorable safety profile (low rates of corrected QT interval prolongation, sedation, weight gain, and akathisia). 9 In phase 1 studies, the pharmacokinetics and safety profiles of brexpiprazole were similar between the Japanese 10 and foreign (Otsuka Pharmaceutical Development & Commercialization, Inc., unpublished data, 2010) patients with SCZ. This suggests that no dosage adjustment may be required based on race. However, generally, Japanese patients account for only a small percentage of the total populations enrolled in the global phase 3 clinical studies of brexpiprazole, and studies conducted in specific ethnic populations are still needed. Therefore, we conducted a 6-week, multicenter, randomized, double-blind, placebo-controlled, phase 2/3 study to evaluate the efficacy, safety, and tolerability of fixed-dose brexpiprazole (1, 2, and 4 mg/day) in Japanese patients with acute SCZ.
METHODS
This study was performed in compliance with the International Conference on Harmonisation Good Clinical Practice Consolidated guideline, local laws, and regulatory requirements in Japan, and the protocol was approved by the institutional review board of Goryokai Hospital and conformed to the provisions of the Declaration of Helsinki. All patients enrolled in the study provided written informed consent.
Patients
Male and female patients were recruited from 148 study sites in Japan. Eligible patients were aged 18 to less than 65 years, diagnosed with SCZ based on the diagnostic criteria as defined in the DSM-IV-TR and confirmed by the Mini International Neuropsychiatric Interview assessment for experiencing acute exacerbation of psychotic symptoms, psychotic disorders, and marked deterioration of normal function by meeting the following criteria at screening and baseline: Clinical Global Impression-Severity (CGI-S) score of ≥4, total Brief Psychiatric Rating Scale (BPRS) score of ≥40, and score of ≥4 for two or more of the BPRS items (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content). Eligibility criteria also included patients who were hospitalized or judged to require hospitalization for acute relapse of SCZ at the time of informed consent, and those with a history of exacerbation or relapse of symptoms when not receiving antipsychotic treatments. We excluded: patients presenting with severe akathisia, clinically significant tardive dyskinesia, or their first episode of SCZ; patients meeting DSM-IV-TR diagnostic criteria other than SCZ; patients with a history of substance abuse or dependence within the past 180 days; and patients receiving electroconvulsive therapy 60 days prior to informed consent. Patients with concurrent diabetes or history of diabetes were also excluded.
Prohibited concomitant medications prior to randomization included benzodiazepines, mood stabilizers, antidepressants, depot/long-acting injectable antipsychotics, and oral/immediate-release intramuscular antipsychotics. Washout periods were required prior to initial dosing of the double-blind treatment on day 1. The washout periods ranged from 3 to 14 days (1.5 cycles) for depot/long-acting injectable antipsychotics, 14 days for aripiprazole, and 7 days for other oral/immediate-release intramuscular antipsychotics and other prohibited concomitant medications. All psychotropic agents, ramelteon, suvorexant, benzodiazepines (except short-term rescue therapy for the treatment of agitation and insomnia), antihistamines (excluding medicines for external application), nonbenzodiazepine sleep aids (except for limited treatment of insomnia), varenicline, supplements containing centrally acting substances (tryptophan and St. John's wort), investigational agents, cytochrome P450 (CYP) 3A4 inhibitors/inducers, and CYP2D6 inhibitors were prohibited during the treatment period.
Study design
This was a randomized, double-blind, placebo-controlled, phase 2/3 study conducted between December 2011 and July 2015 to evaluate the efficacy and safety of three doses of brexpiprazole (ClinicalTrials.gov identifier: NCT01451164). The study consisted of a pre-treatment screening period of ≤14 days, 6 weeks of double-blind treatment, and 30 days of follow-up. After the patients had provided written informed consent, a screening examination was conducted. Patients were hospitalized for the duration of the treatment period. However, patients whose condition remained stable from the assessment at week 3 onward were allowed to transfer to outpatient status or temporarily leave the hospital at the discretion of the investigator or sub-investigator.
Using an interactive web response system, eligible patients were randomized into one of the four treatment groups (1 mg, 2 mg, or 4 mg brexpiprazole, or placebo). Investigators, sub-investigators, and patients were blinded to the treatment randomization codes throughout the study. All doses of study medication were administered orally, once a day. The first week (day 1 to day 7) was set as the titration period. Patients in the brexpiprazole 2-and 4-mg groups received 1 mg/day on days 1-4 and then 2 mg/day on days 5-7. Patients in the 4-mg group received 4 mg/day from day 8. Posttreatment observation was performed 7 and 30 days after the final dose of the study medication in patients who did not proceed on to the extension study.
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Assessments Efficacy
The primary endpoint was the change from baseline to week 6 in PANSS total score. The secondary endpoints were: changes from baseline to week 6 in the CGI-S score, PANSS Positive subscale score, PANSS Negative subscale score, PANSS Excited Component score, and PANSS Marder Factor scores. 12 The secondary endpoints also included the Clinical Global Impression-Improvement (CGI-I) score and response rate, defined as ≥30% reduction in the PANSS total score from baseline or CGI-I score of 1 (very much improved) or 2 (much improved) at week 6.
Safety
The safety variables examined included treatmentemergent adverse events (TEAE), bodyweight, body mass index (BMI), waist circumference, 12-lead electrocardiogram (ECG), vital signs, clinical laboratory tests, Columbia Suicide Severity Rating Scale, Barnes Akathisia Rating Scale, Abnormal Involuntary Movement Scale, and Drug-Induced Extrapyramidal Symptoms Scale.
Statistical analysis
Sample sizes were calculated based on an expected differences of 8.5 points (SD, 20 points) between the brexpiprazole (for 2-and 4-mg doses) and placebo groups in the primary endpoint analysis. A sample size of 110 evaluable patients per group was projected to achieve 80% power at an alpha level of 0.025 (two-sided).
All randomized patients who had received at least one dose of the study drug during the treatment period and who had been given a PANSS total score rating at baseline and at least one other timepoint after study drug administration were included in the efficacy population. All patients to whom the study drug had been administered at least once during the treatment period and for whom any post-dose safety-related data had been obtained were included in the safety population.
The primary endpoint was analyzed using the mixed model for repeated measures analysis. A twostep testing approach was used to control the family-wise error rate of multiple comparisons. 13 If the average effect of 2-and 4-mg of brexpiprazole compared with placebo was statistically significant (P ≤ 0.05), comparisons for each individual dosage versus placebo were tested at a significance level of 0.05. For secondary endpoints, changes in the CGI-S score, PANSS Positive subscale score, PANSS Negative subscale score, PANSS Excited Component score, and PANSS Marder Factor scores were analyzed using mixed model for repeated measures analysis. CGI-I score was analyzed using the Wilcoxon two-sample test and response rate was analyzed using the χ included in the safety and efficacy populations, respectively. In total, 291/459 (63.4%) patients completed the study: 72/115 (62.6%), 81/115 (70.4%), 68/113 (60.2%), and 70/116 (60.3%) in the brexpiprazole 1-mg, 2-mg, 4-mg, and placebo groups, respectively (Fig. 1) . Occurrence of TEAE (15.3%) and withdrawal of consent (12.6%) were the most frequent reasons for discontinuation across all treatment groups.
Demographic and baseline clinical characteristics were similar in all treatment groups ( Table 1 ). The severity of the underlying disease at baseline was similar among the treatment groups. At baseline, the mean PANSS total score was between 96.6 and 98.8 and the mean CGI-S score was between 4.7 and 4.8 in each treatment group. During the treatment period, anticholinergic and antiparkinson drugs for treatment of extrapyramidal symptoms were administered to 9.6%, 11.3%, 9.7%, and 4.3% of the patients in the brexpiprazole 1-mg, 2-mg, 4-mg, and placebo groups, respectively. Concomitant use of benzodiazepine (lorazepam and diazepam) was reported in 70.4%, 67.8%, 72.6%, and 70.7% of the patients in the brexpiprazole 1-mg, 2-mg, 4-mg, and placebo groups, respectively. Concomitant use of nonbenzodiazepine sleep aids was reported in 20.9%, 27.8%, 21.2%, and 19.8% of the patients in the brexpiprazole 1-mg, 2-mg, 4-mg, and placebo groups, respectively.
Efficacy
For the primary endpoint, the average effect of brexpiprazole 2 mg and 4 mg on the change in the PANSS total score from baseline to week 6 was statistically significant compared with placebo (least square [LS] mean difference − 5.59, P = 0.0298). Individual comparisons of brexpiprazole 2 mg and 4 mg with placebo demonstrated that brexpiprazole 2 mg resulted in a statistically significantly reduced PANSS total score versus placebo (LS mean difference − 7.32, P = 0.0124) at week 6 (Table 2) , and this improvement was observed from week 3 and at every subsequent assessment through week 6 (Fig. 2) . Brexpiprazole 4 mg showed numerical improvements in the PANSS total score compared with placebo at week 6 (LS mean difference − 3.86, P = 0.1959) ( Table 2 ). Brexpiprazole 1 mg showed only minimal change from baseline at week 6 in PANSS total score (Table 2) .
Brexpiprazole 2 mg and 4 mg showed significant improvements over placebo for the secondary endpoints, PANSS Negative subscale score, and PANSS Marder Negative Factor score (Table 2) . Also, brexpiprazole 2 mg showed significant improvement over placebo for the PANSS Marder Disorganized Thought Factor score ( Table 2) . Brexpiprazole 1 mg showed significant improvement over placebo for the PANSS Marder Negative Factor score ( Table 2 ). The CGI-I score at week 6 for the brexpiprazole 1-mg, 2-mg, 4-mg, and placebo groups was 3.90, 3.49, 3.78, and (Table 2 ).
Safety and tolerability
TEAE occurring during the study were reported in 70.4% (81/115), 69.3% (79/114), 65.5% (74/113), and 76.7% (89/116) of the patients in the brexpiprazole 1-mg, 2-mg, 4-mg, and placebo groups, respectively ( Table 3 ). The most frequent TEAE in all treatment groups was worsening of SCZ (Table 3) . TEAE defined as ≥5% in brexpiprazole treatment groups and ≥2 times the rate of placebo were vomiting, elevated blood prolactin, diarrhea, nausea, and dental caries (Table 3) , and all of these cases were mild or moderate in severity. In general, most TEAE were mild or moderate in severity. In all treatment groups, the most frequently reported serious TEAE and TEAE leading to discontinuations was worsening of SCZ. One patient in the brexpiprazole 4-mg group died 13 days after the final dose because of asphyxia caused by inhalation of vomit induced by high alcohol intake. It was judged to be not related to brexpiprazole.
Akathisia was reported less frequently in the brexpiprazole treatment groups than in the placebo group (Table 3 ). The onset of akathisia most frequently occurred during the first 3 weeks of treatment, and there were no treatment discontinuations caused by akathisia. The mean weight changes were −0.67 kg (1 mg), −0.04 kg (2 mg), −0.50 kg (4 mg), and −1.16 kg (placebo) at the final assessment. Potentially clinically relevant increases in bodyweight (≥7%) were higher in the brexpiprazole groups (4.3% [1 mg], 5.3% [2 mg], and 2.7% [4 mg]) than in the placebo group (0.9%). Changes from baseline to the last visit in laboratory parameters are indicated in Table 4 . Incidence of categorical increase in prolactin level is shown in Table S1 . There were no significant clinical mean changes from baseline in laboratory parameters, vital signs, or ECG parameters in any of the brexpiprazole groups or the placebo group. There were no clinically significant changes in Drug-Induced Extrapyramidal Symptoms Scale, Barnes Akathisia Rating Scale, Abnormal Involuntary Movement Scale, or Columbia Suicide Severity Rating Scale scores in any of the brexpiprazole groups or in the placebo group. 
DISCUSSION
This short-term placebo-controlled study was conducted in Japanese adult patients with acute SCZ who were markedly ill. The study design was similar to the previous phase 3 studies. 6, 7 In this study, brexpiprazole 2 mg showed a significant improvement in the PANSS total score compared with placebo after 6 weeks, and this improvement was observed from week 3 and at every subsequent assessment through week 6, which is similar to what was observed in the study conducted by Correll et al. 7 Brexpiprazole 4 mg showed a numerical improvement at week 6 in the PANSS total score. This result is different to those of previous phase 3 studies in which brexpiprazole 4 mg showed significant improvements. 6, 7 In our study, the reason for the smaller treatment response in the brexpiprazole 4-mg group compared to the 2-mg group cannot be determined with certainty. Patients receiving previous high-dose polypharmacy may be unsuitable for evaluation of drug efficacy due to a combination of various factors impeding evaluation of drug efficacy and this could, in part, be attributable to the differences in the results observed. Therefore, we performed subgroup analyses in nonpolypharmacy patients as post-hoc analyses (File S1). These post-hoc analyses showed that improvements in the PANSS total score with brexpiprazole 2 and 4 mg were greater than those observed in the primary analysis, and were significantly greater compared with placebo. The reason for the smaller treatment response in the brexpiprazole 4-mg group compared with the 2-mg group could be a combination of several factors, including the influence of polypharmacy. Treatment with brexpiprazole was generally safe and well tolerated. Each completion rate in the brexpiprazole groups was high, and incidences of TEAE across all brexpiprazole groups were less frequent than in the placebo group. The most serious TEAE and TEAE leading to discontinuation were related to the underlying disease of SCZ. Akathisia is a common side-effect of second-generation antipsychotics. 14 The incidence rates of akathisia in the brexpiprazole treatment groups were lower compared with the placebo group, and no events of akathisia led to discontinuation. 6 This result was consistent with that of two previous studies. 6, 7 At final assessment, there was no mean weight gain in patients in any of the treatment arms of the study. The incidence of the elevated blood prolactin reported as a TEAE in the brexpiprazole 4-mg group was higher than that in the brexpiprazole 1-and 2-mg groups; however, the mean increase in prolactin concentration from baseline to last visit in the brexpiprazole 4-mg group was similar to that in the brexpiprazole 1-and 2-mg groups and no clinically relevant sequelae related to elevated prolactin were noted. This tendency was similar to the results of a phase 1 study in Japanese patients with SCZ, where brexpiprazole 4 and 6 mg showed dose-related transient serum prolactin increase on day 1 and all brexpiprazole doses (i.e. 1, 4, and 6 mg) showed similar serum prolactin levels at baseline and on day 14 following multiple dosing of brexpiprazole.
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Safety and efficacy data from this study suggest that brexpiprazole will provide a valuable therapeutic option for treating Japanese patients with SCZ.
Limitations of this study were the short duration to demonstrate meaningful clinical changes in negative symptoms and the lack of an active comparator. This study addressed the efficacy of brexpiprazole for the treatment of acute SCZ; further studies are expected to determine the long-term safety and effectiveness of brexpiprazole in Japanese patients with SCZ.
In conclusion, results from this study support the efficacy, safety, and tolerability of brexpiprazole in Japanese adult patients with acute SCZ.
